Author

Si-Yuan Cui

h-index 9 View on Semantic Scholar

We have 3 of 56 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning

This Review critically evaluates CD38 biology, Fc-mediated immune-effector mechanisms, immune remodeling, clinical evidence, resistance, safety, laboratory interferences, biomarker evidence, and clinical positioning of anti-CD38 antibodies, with multiple myeloma as the central reference disease.

Li-Ming Yu, Chang-Nian Li, Da-Dong Guo et al. · Frontiers in Immunology · 0 citations

Open access Sep 2026

Other primary malignancies are associated with inferior survival in multiple myeloma: a single-center matched retrospective cohort study

Lung and prostate cancers were the most common OPMs in this cohort, highlighting the need for heightened clinical attention to these malignancies in patients with MM.

Chang-Nian Li, Ya-Ru Wang, Lu-Lu Li et al. · Frontiers in Oncology · 0 citations

Open access Aug 2026

Biomarker implications of gene editing in hematologic diseases: latest updates from ASH 2025

Overall, ASH 2025 suggests a shift from achieving gene editing to quantifying efficacy, durability, and safety, with standardized biomarker frameworks likely to play an increasingly important role in future clinical translation.

Ze-Zhou Zang, Wei Zheng, Rui-Rong Xu et al. · Biomarker Research · 0 citations